Navigation Links
Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
Date:9/21/2009

of the LipiScan system, the only FDA cleared product to detect lipid core plaque and the InfraReDx experience in over 400 patients. The commercially available LipiScan(TM) Coronary Imaging System will be displayed in the "Emerging Technologies" section at booth # 2410.

  • References
    • Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Clinical Progress Series. Circulation 1989; 79:733-743.
    • Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors, and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-813.

About InfraReDx, Inc.

InfraReDx, Inc., headquartered in Burlington, Massachusetts, was founded in 1998 and is a privately-funded medical device company developing a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. For more information, visit www.infraredx.com.

About TCT 2009

Transcatheter Cardiovascular Therapeutics (TCT) is organized by the Cardiovascular Research Foundation, which is dedicated to research and education in the broad subspecialty of interventional cardiology and endovascular medicine. TCT is scheduled from Monday, September 21(st) to Friday, September 25(th), in San Francisco, CA. at the Moscone Center. This scientific meeting is one of the world's largest events for those performing cardiac diagnostics and interventions. This meeting is the primary annual meeting for the world-wide interventional cardiology community. For more information, visit www.tctconference.com

    Company Co
'/>"/>
SOURCE InfraReDx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. New Web Site Will Help Pennsylvanians Learn About, Protect Against Novel H1N1 Flu
2. The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
3. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
4. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
5. Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
6. Solution to PREVENT Novel H1N1 (Swine Flu) From Closing Down Schools!
7. The Cosmetic Bootcamp LLC Announces Novel Presentations at Its 3rd Annual Marketing and Management Symposium
8. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
9. Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates
10. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
11. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 17, 2014 Giving patients adrenaline after they suffer a ... their prospects of surviving long-term, according to new research ... of patients who have a cardiac arrest get adrenaline, ... arrest for decades," said Dr. Steve Lin, an emergency ... despite advances in medical treatment, long-term survival rates of ...
(Date:4/17/2014)... the leading weapon against the deadly disease could be ... indicating it simply needs to be administered differently. , ... anti-malarial drug chloroquine in treating and preventing the mosquito-bourne ... a million people each year around the world. , ... chloroquine, but research carried out at the Australian National ...
(Date:4/16/2014)... Calif. Consider the marvel of the embryo. It begins ... function as they multiply to become the cells of our ... the body. , Now, in a feat of reverse tissue ... genetic coding that allows embryonic cells to proliferate and transform ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
(Date:4/16/2014)... 16, 2014 According to a new study, endoscopists, ... with one to two small polyps are consistent with ... may be an appropriate target for quality indicators. This ... adherence to guidelines for timing of repeat colonoscopy after ...
Breaking Medicine News(10 mins):Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3
... workers 85 percent rate workplace safety first in ... leave, minimum wage, paid sick days, overtime pay and the ... from the National Opinion Research Center at the University of ... with Workplace Safety," draws on dozens of surveys and polls ...
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay News) ... in patients with nerve pain stemming from injuries or ... chronic nerve pain were taught to take a single ... three times a day, for five days. The cannabis ...
... Specifically asking young women during visits to family planning ... to become pregnant a type of intimate-partner violence ... the women would continue to experience such pressures, according ... the UC Davis School of Medicine. Young women ...
... , This release is available in French ... debated by clinicians, researchers, legislators and the public at large ... for pain, which may not always be effective and may ... Health Centre (MUHC) and McGill University researchers provides evidence that ...
... It may soon be possible to identify patients who ... the blood specific to the disease. These findings are ... issue of Nature and conducted by doctors ... techniques to understand infections. Tuberculosis (TB) is ...
... News) -- While the hormone oxytocin makes people more trusting, ... Oxytocin -- a naturally occurring hormone that functions as ... role in social behavior. Increased levels of the hormone have ... generosity and trust, but it hasn,t been known whether this ...
Cached Medicine News:Health News:Workers rate safety most important workplace issue in new Labor Day study 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 2Health News:Study finds asking about pregnancy coercion and intimate-partner violence can reduce their incidence 3Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 3Health News:Oxytocin Increases Trust, Not Gullibility 2
(Date:1/15/2014)... Jan. 15, 2014 The Cadence Fitness & Health ... by the Medical Fitness Association, a non-profit organization assisting ... full potential. The Cadence Fitness & Health Center is ... and second in the Chicagoland area. "The ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 23 Neurobiological Technologies, Inc. (Nasdaq: NTII ) ("NTI") ... extraordinary dividend of $0.18 per share of common stock, which ... record as of November 30, 2009. The December 9, 2009 ... pursuant to a plan of complete liquidation and dissolution and ...
... Calif., Nov. 23 Advanced Sterilization Products (ASP), ... today the acquisition by its French affiliate, Apsis ... of innovative disinfection processes and technologies to prevent ... disclosed. , Gloster Europe designs and markets ...
Cached Medicine Technology:Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2
... FalciVax is a two ... blood for the detection of ... protein-2 (Pf. HRP-2) and P. ... can also be used for ...
Malaria Pf. Assay Range...
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Medicine Products: